Heike Luise Pahl

Heike Luise Pahl

Auto-generated profile, based on publicly available information

Heike Luise Pahl

Department of Hematology/Oncology, Medical Center - University of Freiburg, Freiburg, Germany

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
APAlessandro Prestipino
Alessandro Prestipino
AEAlica J. Emhardt
Alica J. Emhardt
KAKonrad Aumann
Konrad Aumann
DODavid O’sullivan
David O’sullivan
SGSivahari P. Gorantla
Sivahari P. Gorantla
RZRobert Zeiser
Robert Zeiser
Recent evidence has revealed that oncogenic mutations may confer immune escape. A better understanding of how an oncogenic mutation affects immunosuppressive programmed death ligand 1 (PD-L1) expression may help in developing new therapeutic strategies. We show that oncogenic JAK2 (Janus kinase 2) activity caused STAT3 (signal transducer and activator of transcription 3) and STAT5 phosphorylation, which enhanced PD-L1 promoter activity and PD-L1 protein expression in JAK2V617F-mutant cells, whereas blockade of JAK2 reduced PD-L1 expression in myeloid JAK2V617F-mutant cells. PD-L1 expression was higher on primary cells isolated from patients with JAK2V617F–myeloproliferative neoplasms (MPNs) compared to healthy individuals and declined upon JAK2 inhibition. JAK2V617F mutational burden, pSTAT3, and PD-L1 expression were highest in primary MPN patient–derived monocytes, megakaryocytes, and platelets. PD-1 (programmed death receptor 1) inhibition prolonged survival in human MPN xenograft and primary murine MPN models. This effect was dependent on T cells. Mechanistically, PD-L1 surface expression in JAK2V617F-mutant cells affected metabolism and cell cycle progression of T cells. In summary, we report that in MPN, constitutive JAK2/STAT3/STAT5 activation, mainly in monocytes, megakaryocytes, and platelets, caused PD-L1–mediated immune escape by reducing T cell activation, metabolic activity, and cell cycle progression. The susceptibility of JAK2V617F-mutant MPN to PD-1 targeting paves the way for immunomodulatory approaches relying on PD-1 inhibition.

15 October 2005 in Blood
Verified
Journal Article
Open access
PDF file
PGPhilipp S. Goerttler
Philipp S. Goerttler
CSCordula Steimle
Cordula Steimle
EMEdith März
Edith März
PJPeter L. Johansson
Peter L. Johansson
BABjörn Andreasson
Björn Andreasson
HPHeike L. Pahl
Heike L. Pahl
Recently, a Jak2V617F mutation has been described in the vast majority of patients with polycythemia vera (PV) as well as in subsets of patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). The question arises whether this mutation is observed in those patients with ET and IMF who have also displayed previously described molecular markers, notably the ability to form endogenous erythroid colonies (EECs), overexpression of polycythemia rubra vera 1 (PRV-1), and decreased c-Mpl expression. We therefore analyzed the Janus kinase 2 (Jak2) DNA sequence, EEC growth, PRV-1 expression, and c-Mpl (myeloproliferative) levels in a cohort of 78 myeloproliferative disorder (MPD) patients (42 ET, 22 PV, and 14 IMF). Presence of the Jak2V617F mutation was very highly correlated with PRV-1 overexpression and the ability to form EECs in all 3 subtypes of MPDs (P < .001). (Blood. 2005;106:2862-2864)

15 April 2013 in Journal of Experimental Medicine
Verified
Journal Article
Open access
JJJonas Jutzi
Jonas Jutzi
RBRuzhica Bogeska
Ruzhica Bogeska
GNGorica Nikoloski
Gorica Nikoloski
CSCorina A. Schmid
Corina A. Schmid
TSThalia S. Seeger
Thalia S. Seeger
HPHeike L. Pahl
Heike L. Pahl
The molecular etiology of myeloproliferative neoplasms (MPNs) remains incompletely understood, despite recent advances incurred through the discovery of several different mutations in MPN patients. We have recently described overexpression of the transcription factor NF-E2 in MPN patients and shown that elevated NF-E2 levels in vivo cause an MPN phenotype and predispose to leukemic transformation in transgenic mice. We report the presence of acquired insertion and deletion mutations in the NF-E2 gene in MPN patients. These result in truncated NF-E2 proteins that enhance wild-type (WT) NF-E2 function and cause erythrocytosis and thrombocytosis in a murine model. NF-E2 mutant cells acquire a proliferative advantage, witnessed by clonal dominance over WT NF-E2 cells in MPN patients. Our data underscore the role of increased NF-E2 activity in the pathophysiology of MPNs.

9 January 2012 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KKKai B. Kaufmann
Kai B. Kaufmann
AGAlbert Gründer
Albert Gründer
THTobias Hadlich
Tobias Hadlich
JWJulius Wehrle
Julius Wehrle
MGMonika Gothwal
Monika Gothwal
HPHeike L. Pahl
Heike L. Pahl
The molecular pathophysiology of myeloproliferative neoplasms (MPNs) remains poorly understood. Based on the observation that the transcription factor NF-E2 is often overexpressed in MPN patients, independent of the presence of other molecular aberrations, we generated mice expressing an NF-E2 transgene in hematopoietic cells. These mice exhibit many features of MPNs, including thrombocytosis, leukocytosis, Epo-independent colony formation, characteristic bone marrow histology, expansion of stem and progenitor compartments, and spontaneous transformation to acute myeloid leukemia. The MPN phenotype is transplantable to secondary recipient mice. NF-E2 can alter histone modifications, and NF-E2 transgenic mice show hypoacetylation of histone H3. Treatment of mice with the histone deacetylase inhibitor (HDAC-I) vorinostat restored physiological levels of histone H3 acetylation, decreased NF-E2 expression, and normalized platelet numbers. Similarly, MPN patients treated with an HDAC-I exhibited a decrease in NF-E2 expression. These data establish a role for NF-E2 in the pathophysiology of MPNs and provide a molecular rationale for investigating epigenetic alterations as novel targets for rationally designed MPN therapies.

10 August 2005 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
HCHolger Cario
Holger Cario
PGPhilipp S. Goerttler
Philipp S. Goerttler
CSCordula Steimle
Cordula Steimle
RLRoss L. Levine
Ross L. Levine
HPHeike L. Pahl
Heike L. Pahl
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

1 June 2004 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
MGM. Griesshammer
M. Griesshammer
SKS. Klippel
S. Klippel
ESE. Strunck
E. Strunck
STS. Temerinac
S. Temerinac
UMU. Mohr
U. Mohr
HPH. L. Pahl
H. L. Pahl